BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16150195)

  • 1. A clinical study of Yigu capsule in treating postmenopausal osteoporosis.
    Zhang RH; Chen KJ; Lu DX; Zhu XF; Ma XC
    Chin J Integr Med; 2005 Jun; 11(2):97-103. PubMed ID: 16150195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study on treatment of postmenopausal osteoporosis by Yigu capsule].
    Zhang RH; Chen KJ; Lu DX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Aug; 24(8):680-4. PubMed ID: 15366587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
    J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
    Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial.
    Jiang Y; Zhang ZL; Zhang ZL; Zhu HM; Wu YY; Cheng Q; Wu FL; Xing XP; Liu JL; Yu W; Meng XW
    Clin Interv Aging; 2014; 9():121-7. PubMed ID: 24426779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
    Bell NH; Bilezikian JP; Bone HG; Kaur A; Maragoto A; Santora AC;
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2792-7. PubMed ID: 12050252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 17beta-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women.
    Giske LE; Hall G; Rud T; Landgren BM
    Osteoporos Int; 2002; 13(4):309-16. PubMed ID: 12030546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.
    Chen T; Li G; Xu Y
    Comput Math Methods Med; 2023; 2023():4846392. PubMed ID: 37455682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.
    Orimo H; Shiraki M; Hayashi Y; Hoshino T; Onaya T; Miyazaki S; Kurosawa H; Nakamura T; Ogawa N
    Calcif Tissue Int; 1994 May; 54(5):370-6. PubMed ID: 8062152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of total flavones of Epimedium leptorrhizum on osteoporosis in ovariectomized rats].
    Cao CY; Liu T; Hui LQ; Hao R
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(10):1913-7. PubMed ID: 25282905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.